Core Viewpoint - The company BaiO Saite-B (02315) has reported significant growth in its 2025 performance forecast, with a notable increase in revenue and net profit, driven by overseas market expansion and recovery in the domestic biopharmaceutical industry [1] Financial Performance - The expected revenue for 2025 is approximately 1.379 billion RMB, representing a year-on-year growth of 40.63% [1] - The net profit attributable to the company's owners is projected to be 173 million RMB, showing a substantial year-on-year increase of 416.37% [1] - The net profit attributable to the company's owners, excluding non-recurring gains and losses, is expected to be 116 million RMB, reflecting a year-on-year growth of 405.39% [1] Asset and Equity Growth - Total assets are anticipated to reach 3.724 billion RMB, an increase of 54.20% compared to the beginning of the period [1] - Equity attributable to the company's owners is projected to be 2.175 billion RMB, marking a significant increase of 160.76% from the beginning of the period [1] Strategic Drivers - The growth in operating performance is primarily attributed to the continuous expansion in overseas markets and the recovery of the domestic biopharmaceutical sector [1] - The company emphasizes an innovation-driven strategy, with sustained high-intensity R&D investment to build core technological barriers, ensuring stable high gross margins [1] - Lean management practices are being implemented to continuously enhance operational efficiency, contributing to rapid improvements in profitability [1]

消息面上，公司昨晚公告业绩预告，预计2025年归属于上市公司股东的净利润为1.62亿-1.82亿元，同比增长384.26%至 443.88%。受益于海外市场的持续拓展，叠加国内生物医药（核心股）行业的复苏回暖，公司营业收入实现高速增长。高壁 垒的技术优势保障业务毛利维持高位，精益化管理举措进一步推动运营效率提升，公司盈利水平得以快速提高。 1月30日，2025年净利同比预增384.26%-443.88%，刺激百奥赛图AH股齐涨。A股一度大涨超18%至78.75元，创上市新高； H股一度飙升超43%至63港元，股价亦创上市新高。 股票频道更多独家策划、专家专栏，免费查阅>> 责任编辑：栎树 ...

格隆汇1月30日｜2025年净利同比预增384.26%-443.88%，刺激百奥赛图AH股齐涨。A股一度大涨超18% 至78.75元，创上市新高；H股一度飙升超43%至63港元，股价亦创上市新高。 消息面上，公司昨晚公 告业绩预告，预计2025年归属于上市公司股东的净利润为1.62亿-1.82亿元，同比增长384.26%至 443.88%。受益于海外市场的持续拓展，叠加国内生物医药行业的复苏回暖，公司营业收入实现高速增 长。高壁垒的技术优势保障业务毛利维持高位，精益化管理举措进一步推动运营效率提升，公司盈利水 平得以快速提高。 ...

盈喜后涨超40%，截至发稿，涨40.91%，报62港元，成交额5841万港元。 消息面上，百奥赛图发布2025年度业绩预告，预计全年实现营收约13.69亿元-13.89亿元，较上年同期增加3.89亿元至4.08亿元，同比增幅为39.61%到 41.65%；预计实现归母净利润约为1.62亿元-1.82亿元，较上年同期增加1.29亿元至1.49亿元，同比大幅增长384.26%至443.88%。 公告称，受益于海外市场的持续拓展，叠加国内生物医药行业的复苏回暖，公司营业收入实现高速增长；高壁垒的技术优势保障业务毛利维持高位，精益化 管理举措进一步推动运营效率提升，公司盈利水平得以快速提高。 编辑/doris ...

本期业绩变化的主要原因：(一)受益于海外市场的持续拓展，叠加国内生物医药行业的复苏回暖，公司 营业收入实现高速增长。(二)高壁垒的技术优势保障业务毛利维持高位，精益化管理举措进一步推动运 营效率提升，公司盈利水平得以快速提高。 格隆汇1月29日丨百奥赛图(688796.SH)公布，经公司财务部门初步测算，预计2025年年度实现营业收入 13.69亿元到13.89亿元，与上年同期相比，将增加3.88亿元到4.08亿元，同比增加39.61%到41.65%。预 计2025年年度实现归属于母公司所有者的净利润1.62亿元到1.82亿元，与上年同期相比，将增加1.29亿 元到1.49亿元，同比增加384.26%到443.88%。预计2025年年度实现归属于母公司所有者的扣除非经常性 损益的净利润1.05亿元到1.25亿元，与上年同期相比，将增加8195.13万元到1.02亿元，同比增加 356.81%到443.88%。 ...

Investment Rating - The report maintains a "Strong Buy" rating for the company [4]. Core Insights - The company has shown continuous strong performance, with significant growth in both domestic and international business segments. In the first half of 2025, it achieved revenue of 387 million yuan and a net profit of 84 million yuan, representing year-on-year growth of 29.38% and 47.81% respectively [1]. - The domestic business is performing robustly, with a revenue increase of 36.7% in the first half of 2025, while international revenue also grew by 22.9% [8]. - The company is benefiting from the increasing emphasis on early-stage research and development in the biopharmaceutical sector, leading to a sustained upward trend in revenue and profit margins over the past three quarters [8]. - The company has successfully developed nearly 60 high-quality GMP-grade products, with significant sales growth in core recombinant protein varieties and other clinical products [8]. - The report projects a positive outlook for the company's net profit, estimating 182 million yuan, 237 million yuan, and 299 million yuan for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 53, 41, and 33 [8]. Financial Data and Valuation - The company is expected to achieve total revenue of 839 million yuan in 2025, with a year-on-year growth rate of 30% [3]. - The projected net profit for 2025 is 182 million yuan, reflecting a 47% increase compared to the previous year [3]. - The current stock price is 57.83 yuan, with a total market capitalization of 9.7 billion yuan [4]. - The company has a low debt-to-asset ratio of 9.3%, indicating strong financial stability [4]. Performance Metrics - The company has shown a significant increase in quarterly revenue, with Q2 2025 revenue reaching 201 million yuan, a 30.95% increase year-on-year [1]. - The gross profit margin remains stable at around 90.5%, indicating strong pricing power and cost management [10]. - The return on equity (ROE) is projected to improve from 5.8% in the trailing twelve months to 9.9% by 2027 [4][10].